Ignite Creation Date:
2025-12-24 @ 7:18 PM
Ignite Modification Date:
2025-12-29 @ 5:48 AM
Study NCT ID:
NCT04610203
Status:
COMPLETED
Last Update Posted:
2020-11-02
First Post:
2020-10-10
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Glycaemic Response, Insulinaemic Response, GLP-1 and GIP Testing of Food Product Lines
Sponsor:
Oxford Brookes University
Organization:
Study Overview
Official Title:
Glycaemic, Insulinaemic, Gastric Inhibitory Polypeptide (GIP) and Glucagon-like Peptide-1 (GLP-1) Response for Glucose, Glucose With 25 g Nutralys S85 Plus and Glucose With 50 g Nutralys S85 Plus
Status:
COMPLETED
Status Verified Date:
2020-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The aim of this study was to compare the glycaemic response, insulinaemic response, GIP response and GLP-1 response to glucose, 25 g Nutralys S85 Plus and 50 g Nutralys S85 Plus using a single-blind, randomised, repeat measure, crossover design trial.
Detailed Description:
The aims of this study were to examine:
* Phase I - the glycaemic response (GR) and insulinaemic response (IR) to:
* 50 g available carbohydrate
* 50 g available carbohydrate + protein (dose 1)
* 50 g available carbohydrate + protein (dose 2)
* Phase II - the GLP-1 and GIP response to:
* 50 g available carbohydrate
* 50 g available carbohydrate + protein (dose 1)
* 50 g available carbohydrate + protein (dose 2)
A single-blind, randomised, repeat measure, crossover design trial was used to study the response following consumption of three meals: one reference meal (50 g available carbohydrate) and two test meals (50 g available carbohydrate with protein dose 1 and 50 g available carbohydrate with protein dose 2). The study was conducted in two phases:
* Phase I: glycaemic response (GR), insulinaemic response (IR)
* Phase II: GLP-1 response and GIP response
* Phase I - the glycaemic response (GR) and insulinaemic response (IR) to:
* 50 g available carbohydrate
* 50 g available carbohydrate + protein (dose 1)
* 50 g available carbohydrate + protein (dose 2)
* Phase II - the GLP-1 and GIP response to:
* 50 g available carbohydrate
* 50 g available carbohydrate + protein (dose 1)
* 50 g available carbohydrate + protein (dose 2)
A single-blind, randomised, repeat measure, crossover design trial was used to study the response following consumption of three meals: one reference meal (50 g available carbohydrate) and two test meals (50 g available carbohydrate with protein dose 1 and 50 g available carbohydrate with protein dose 2). The study was conducted in two phases:
* Phase I: glycaemic response (GR), insulinaemic response (IR)
* Phase II: GLP-1 response and GIP response
Study Oversight
Has Oversight DMC:
False
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
Secondary ID Infos
| Secondary ID | Type | Domain | Link | View |
|---|---|---|---|---|
| pfact 9806 | OTHER | Oxford Brookes University | View |